Get the Stockscreener App
2.13
3.90%
0.08
After Hours:
2.15
0.02
+0.94%
Immuneering Corp stock is traded at $2.13, with a volume of 154.17K.
It is up +3.90% in the last 24 hours and up +5.97% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$2.05
Open:
$2.06
24h Volume:
154.17K
Relative Volume:
0.03
Market Cap:
$63.46M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-1.1036
EPS:
-1.93
Net Cash Flow:
$-49.31M
1W Performance:
+4.41%
1M Performance:
+5.97%
6M Performance:
+53.24%
1Y Performance:
-73.00%
1-Day Range:
$2.04
$2.1595
1-Week Range:
$2.03
$2.25
52-Week Range:
$1.00
$8.89
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
2.13 | 63.46M | 317.00K | -53.47M | -49.31M | -1.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Immuneering shares retain Outperform rating amid Phase 2a progress for IMM-1-104 - Investing.com
Brokerages Set Immuneering Co. (NASDAQ:IMRX) Price Target at $12.60 - Defense World
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor - Yahoo Finance
Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Consensus Target Price from Brokerages - MarketBeat
Immuneering Corp. Reports Q3 Loss, Highlights Progress - TipRanks
Immuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 6.7% - MarketBeat
Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug - Yahoo Finance
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Uncovering the Potential of Immuneering Corp (IMRX) Stock - The InvestChronicle
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
FDA grants orphan drug status to Immuneering's cancer treatment - Investing.com
FDA grants orphan drug status to Immuneering's cancer treatment By Investing.com - Investing.com Canada
Financial Health Check: Examining Immuneering Corp (IMRX)’s Key Ratios - The Dwinnex
Immuneering Corp Cl A (IMRX-Q) QuotePress Release - The Globe and Mail
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World
Renaissance Technologies LLC Takes Position in Immuneering Co. (NASDAQ:IMRX) - MarketBeat
IMRX’s Stochastic Averages Dip: Analyzing Immuneering Corp’s Stock Performance - The InvestChronicle
Marshall Wace LLP Makes New Investment in Immuneering Co. (NASDAQ:IMRX) - MarketBeat
The time has not yet come to remove your chips from the table: Immuneering Corp (IMRX) - SETE News
A stock that deserves closer examination: Immuneering Corp (IMRX) - US Post News
Immuneering Corp’s Market Journey: Closing Strong at 2.47, Up 4.22 - The Dwinnex
Immuneering stock maintains Outperform rating on positive prospects - Investing.com
How does Immuneering Corp (IMRX) change from a tortoise to a hare? - SETE News
Understanding the Risks of Investing in Immuneering Corp (IMRX) - Knox Daily
Immuneering Corp (IMRX) Stock: A Year of Decreases and Increases - The InvestChronicle
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX)’s stock chart: A technical perspective - US Post News
Ratio Revelations: Immuneering Corp (IMRX)’s Financial Metrics in the Spotlight - The Dwinnex
Biotech Surges Premarket Following Positive Phase 2a Observations - MSN
Immuneering Corp (IMRX) Recovers 161.00% From Low: Sitting In The Catbird Seat? - Stocks Register
Immuneering Corp [IMRX] stock for 1,160,181 USD was sold by Cormorant Asset Management, LP - Knox Daily
You might want to take a look at Immuneering Corp (IMRX) now - SETE News
Immuneering Corp [IMRX] Insider Cormorant Asset Management, LP sells 400,000 Shares - Knox Daily
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
Immune Price Drop Is An Entry Opportunity - Top Buzz Times
IMUX’s 2023 Market Saga: Unraveling the Story of Gains and Losses - The InvestChronicle
Analytical Overview: ImmunityBio Inc (IBRX)’s Ratios Tell a Financial Story - The Dwinnex
Market Momentum Report: Immunic Inc (IMUX)’s Negative Close at 1.60 - The Dwinnex
Inflection Point Acquisition Corp. II (NASDAQ:IPXX) Shares Bought by Berkley W R Corp - MarketBeat
Armored car company tires reverse domain name hijacking - Domain Name Wire
Daily Market Movement: Immuneering Corp (IMRX) Sees a -10.59 Decrease, Closing at 2.87 - The Dwinnex
IOH announces stock split to enhance investor participation - Telecompaper EN
Impax Asset Management Group (LON:IPX) Stock Passes Below Fifty Day Moving Average of $383.00 - MarketBeat
Rhumbline Advisers Acquires Shares of 67,184 Immunome, Inc. (NASDAQ:IMNM) - Defense World
ImpediMed Expands U.S. Market Coverage - TipRanks
IDP Education Reports Substantial Shareholder Changes - TipRanks
Analysts review Immunome Inc’s rating - Knox Daily
Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):